The real-world study of the clinical characteristics, diagnosis, and treatment of advanced pancreatic cancer in China

Autor: Jiujie Cui, Qihan Fu, Xiaobing Chen, Yanling Wang, Qi Li, Feng Wang, Zhihua Li, Guanghai Dai, Yusheng Wang, Hongmei Zhang, Houjie Liang, Jun Zhou, Liu Yang, Fenghua Wang, Leizhen Zheng, Xiaofeng Chen, Ping Gong, Jiang Liu, Ying Yuan, Lin Wang, Yuejuan Cheng, Jun Zhang, Yuhong Zhou, Weijian Guo, Xianbao Zhan, Zhengyun Zou, Da Li, Shan Zeng, Enxiao Li, Zhiwei Li, Zan Teng, Dan Cao, Jie Kan, Jianping Xiong, Ming Quan, Jiayu Yao, Haiyan Yang, Liwei Wang

Publikováno v: Journal of Pancreatology, Vol 7, Iss 1, Pp 1-9 (2024)

Objective:. Real-world diagnostic and treatment data for pancreatic cancer in China are lacking. As such, the present study investigated the clinical characteristics, diagnosis, and treatment of advanced pancreatic cancer (including locally advanced

Externí odkaz: https://doaj.org/article/2e0a1c4b680346ddb97288531b46b3bf

Case Report: Partial response to single-agent pembrolizumab in a chemotherapy-resistant metastatic pancreatic cancer patient with a high tumor mutation burden

Autor: Mengyao Dai, Jianpeng Sheng, Qi Zhang, Jianxin Wang, Qihan Fu, Tingbo Liang

Publikováno v: Frontiers in Oncology, Vol 13 (2023)

Single-agent immune checkpoint blockade has shown no clinical benefits in pancreatic cancer. Recently, the programmed cell death protein 1 (PD-1) antibody pembrolizumab has been recommended as a treatment option for high tumor mutational burden (TMB)

Externí odkaz: https://doaj.org/article/2e09c34e0f1e4f67a5584bdb2f79c301

Dynamic alterations of genome and transcriptome in KRAS G13D mutant CRC PDX model treated with cetuximab

Autor: Hangyu Zhang, Liyun Yuan, Lulu Liu, Cong Yan, Jinming Cheng, Qihan Fu, Zhou Tong, Weiqin Jiang, Yi Zheng, Peng Zhao, Guoqing Zhang, Weijia Fang

Publikováno v: BMC Cancer, Vol 20, Iss 1, Pp 1-10 (2020)

Abstract Background KRAS mutations have been characterized as the major predictive biomarkers for resistance to cetuximab treatment. However, studies indicate that not all KRAS mutations are associated with equivalent treatment outcomes. KRAS G13D mu

Externí odkaz: https://doaj.org/article/58e11ca55c2046d6a35b82cee15250e5

Expert consensus on multidisciplinary therapy of colorectal cancer with lung metastases (2019 edition)

Autor: Jian Li, Ying Yuan, Fan Yang, Yi Wang, Xu Zhu, Zhenghang Wang, Shu Zheng, Desen Wan, Jie He, Jianping Wang, Yi Ba, Chunmei Bai, Li Bai, Wei Bai, Feng Bi, Kaican Cai, Muyan Cai, Sanjun Cai, Gong Chen, Keneng Chen, Lin Chen, Pengju Chen, Pan Chi, Guanghai Dai, Yanhong Deng, Kefeng Ding, Qingxia Fan, Weijia Fang, Xuedong Fang, Fengyi Feng, Chuangang Fu, Qihan Fu, Yanhong Gu, Yulong He, Baoqing Jia, Kewei Jiang, Maode Lai, Ping Lan, Enxiao Li, Dechuan Li, Jin Li, Leping Li, Ming Li, Shaolei Li, Yexiong Li, Yongheng Li, Zhongwu Li, Xiaobo Liang, Zhiyong Liang, Feng Lin, Guole Lin, Hongjun Liu, Jianzhong Liu, Tianshu Liu, Yunpeng Liu, Hongming Pan, Zhizhong Pan, Haiping Pei, Meng Qiu, Xiujuan Qu, Li Ren, Zhanlong Shen, Weiqi Sheng, Chun Song, Lijie Song, Jianguo Sun, Lingyu Sun, Yingshi Sun, Yuan Tang, Min Tao, Chang Wang, Haijiang Wang, Jun Wang, Shubin Wang, Xicheng Wang, Xishan Wang, Ziqiang Wang, Aiwen Wu, Nan Wu, Lijian Xia, Yi Xiao, Baocai Xing, Bin Xiong, Jianmin Xu, Jianming Xu, Nong Xu, Ruihua Xu, Zhongfa Xu, Yue Yang, Hongwei Yao, Yingjiang Ye, Yonghua Yu, Yueming Yu, Jinbo Yue, Jingdong Zhang, Jun Zhang, Suzhan Zhang, Wei Zhang, Yanqiao Zhang, Zhen Zhang, Zhongtao Zhang, Lin Zhao, Ren Zhao, Fuxiang Zhou, Jian Zhou, Jing Jin, Jin Gu, Lin Shen

Publikováno v: Journal of Hematology & Oncology, Vol 12, Iss 1, Pp 1-11 (2019)

Abstract The lungs are the second most common site of metastasis for colorectal cancer (CRC) after the liver. Rectal cancer is associated with a higher incidence of lung metastases compared to colon cancer. In China, the proportion of rectal cancer c

Externí odkaz: https://doaj.org/article/299498323d604a07bdf5615aea06cb57

Molecular Profiling–Based Precision Medicine in Cancer: A Review of Current Evidence and Challenges

Autor: Qi Zhang, Qihan Fu, Xueli Bai, Tingbo Liang

Publikováno v: Frontiers in Oncology, Vol 10 (2020)

Matched therapy based on next-generation sequencing is now a part of routine care to guide the treatment of patients with advanced solid tumors. However, whether and to what extent patients can benefit from this strategy on a large scale remains unce

Externí odkaz: https://doaj.org/article/90293b91a3aa4b36b22fb1c30c3664d7